XOMA (XOMA) Competitors

Myriad Genetics (NASDAQ:MYGN) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Which has higher valuation and earnings, MYGN or XOMA?

XOMA has lower revenue, but higher earnings than Myriad Genetics. XOMA is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$837.60M	1.06	-$263.30M	-$1.41	-6.90
XOMA	$10.22M	24.31	-$40.83M	-$2.07	-10.02

Does the MarketBeat Community prefer MYGN or XOMA?

Myriad Genetics received 34 more outperform votes than XOMA when rated by MarketBeat users. However, 65.67% of users gave XOMA an outperform vote while only 52.78% of users gave Myriad Genetics an outperform vote.

Company	Underperform	Outperform
Myriad Genetics	Outperform Votes 474 52.78%	Underperform Votes 424 47.22%
XOMA	Outperform Votes 440 65.67%	Underperform Votes 230 34.33%

Do analysts prefer MYGN or XOMA?

Myriad Genetics currently has a consensus target price of $21.89, indicating a potential upside of 125.00%. XOMA has a consensus target price of $72.00, indicating a potential upside of 247.16%. Given XOMA's stronger consensus rating and higher possible upside, analysts clearly believe XOMA is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.20
XOMA	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor MYGN or XOMA?

In the previous week, XOMA had 22 more articles in the media than Myriad Genetics. MarketBeat recorded 28 mentions for XOMA and 6 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.48 beat XOMA's score of 0.74 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA	3 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, MYGN or XOMA?

Myriad Genetics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, XOMA has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Is MYGN or XOMA more profitable?

Myriad Genetics has a net margin of -14.09% compared to XOMA's net margin of -151.34%. Myriad Genetics' return on equity of -4.51% beat XOMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-14.09%	-4.51%	-3.07%
XOMA	-151.34%	-24.95%	-9.64%

Do institutionals & insiders hold more shares of MYGN or XOMA?

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by company insiders. Comparatively, 7.2% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Myriad Genetics beats XOMA on 10 of the 18 factors compared between the two stocks.